Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (465)	1/23/2010 1:47:43 PM
From: Dwayne Hines	Respond to of 534

IR indicated a joint announcement with Merial/Vical should be on the way soon. Looks like things are picking up here.

To: Gary105 who wrote (465)	1/25/2010 7:57:42 PM
From: Dwayne Hines	Respond to of 534

animalfriends.org.uk “Chief executive Vijay Samant also relayed company beliefs that the development was an important step towards a similar type of vaccine for humans.”

To: Gary105 who wrote (465)	2/16/2010 8:32:10 AM
From: Dwayne Hines	1 Recommendation Read Replies (1) \| Respond to of 534

Great news - press release just out. From the release - "The approval of ONCEPT is a milestone in the cancer vaccine field and a significant advancement for our DNA delivery technology platform," said Vijay B. Samant, Vical's President and Chief Executive Officer. "Therapeutic vaccines -- the holy grail of vaccinology -- are delivered after disease onset to impede disease progress for the patient's benefit. We believe this achievement is a major step toward the initial approvals of therapeutic vaccines for humans." This could be huge.\!